# MOTS-c legal status, FDA 503A category, and MOTS-c peptide compounding access > MOTS-c legal status: the MOTS-c peptide is not an FDA-approved drug, is sold as a research chemical, and is individually named on the FDA PCAC July 23-24, 2026 agenda as a substance being considered for the 503A bulks list. General information. Access is under active FDA review and may expand in 2026 — anchored on one fact: MOTS-c is named on the July 2026 PCAC agenda. What that does, and does not, mean. ## The short version Here is the MOTS-c legal status in plain terms. MOTS-c is not an FDA-approved drug, and it is sold only as a research chemical for laboratory use. But it is not sitting still: the FDA's advisory committee on pharmacy compounding has put MOTS-c on the published agenda for its meeting on July 23-24, 2026, as a substance "being considered for inclusion on the 503A Bulks List." That is a scheduled discussion, not a decision — being *under evaluation* is not the same as being approved or listed. This page explains the framework and what a discussion can and cannot change. ## The Current Fact: Not FDA-Approved, Under Evaluation MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is **not** an FDA-approved drug for any indication [16]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) [16]. MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation [18]. Being under evaluation is not the same as being on the bulks list or approved for compounding. Importantly, the audited regulatory record does **not** assign MOTS-c a numbered 503A category; its present-tense status is *scheduled for PCAC evaluation* [18]. ### What is the FDA 503A status of MOTS-c? MOTS-c is not FDA-approved and is not on the 503A bulks list; it is named on the published agenda of the July 23-24, 2026 PCAC meeting as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [16][18]. The audited record assigns it no numbered category — its status is *scheduled for evaluation*, which is a step in the process, not an outcome. ## How 503A and 503B Compounding Work Two sections of the FD&C Act govern compounding [16]. **Section 503A** covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. **Section 503B** covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [16]. A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on the relevant FDA bulks list [16]. A substance that is merely under evaluation does not meet that bar simply by being discussed. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding [16]. ## What the July 2026 PCAC Agenda Does and Does Not Mean MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both free-base and acetate forms [18]. The same agenda also lists BPC-157, TB-500, and KPV [18]. That listing is a scheduled evaluation and discussion **only**. It is not a listing decision, not a reclassification, and not a change in MOTS-c's current status [18]. A PCAC discussion is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking informed by — but not determined by — the committee [16]. Being on the agenda means MOTS-c is in the process; it does not mean an outcome, and no outcome should be assumed or dated [18]. This is the forward-leaning part of the picture, kept honest: access *may* expand if FDA acts after evaluation, but "may" is doing real work in that sentence. Nothing here asserts that any reclassification, listing, or removal has occurred or will occur on any date [16]. ## How Legally Compounded Peptide Access Works In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [17]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [17]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded, nor does it remove the need for a legitimate prescriber-patient relationship and a valid prescription [17]. The ingredient-eligibility caveat is the binding one: a compounder may use an active ingredient only if it is eligible under the 503A/503B rules, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [17]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. ### Can you get MOTS-c from a compounding pharmacy? In general, a compounding pharmacy may prepare a substance only when it is eligible under the 503A/503B framework and a licensed prescriber has issued a valid patient-specific prescription [16][17]. MOTS-c is not FDA-approved and is currently under PCAC evaluation rather than on the bulks list, so its eligibility is unsettled; this digest names no pharmacy and gives no dosing [18]. --- A cobalt-glazed azulejo panel of the MOTS-c record — the mitochondrial peptide's metabolic and exercise-mimetic findings set tile by tile and cited to source, the empty human-trial squares left openly unglazed, and the FDA 503A standing painted before anything else; no clinic behind the panel and nothing here dispensed or sold.